Registry-derived stage (RD-Stage) for capturing cancer stage at diagnosis for endometrial cancer

• Published in: BMC cancer 2023-12, Vol.23 (1), p.1222-1222, Article 1222
• Main Authors: Evans, S M, Ivanova, K, Rome, R, Cossio, D, Pilgrim, Chc, Zalcberg, J, Antill, Y, Blake, L, Du Guesclin, A, Garrett, A, Giffard, D, Golobic, N, Moir, D, Parikh, S, Parisi, A, Sanday, K, Shadbolt, C, Smith, M, Te Marvelde, L, Williams, K
• Format: Article
• Language: English
• Subjects: (MeSH Headings) registries; Cancer; Cancer registries; Carcinoma; Clinical trials; Development and progression; Diagnosis; Disease; Electronic health records; Endometrial cancer; Endometrium; Epidemiology; Gynecology; Histology; Medical prognosis; Medical records; Medical screening; Melanoma; Metastases; Metastasis; Methods; Neoplasm staging; Pathology; Prostate; TNM Stage; Tumor staging; Tumors; Uterine cancer; Working groups
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11615-6

Capture of cancer stage at diagnosis is important yet poorly reported by health services to population-based cancer registries. In this paper we describe current completeness of stage information for endometrial cancer available in Australian cancer registries; and develop and validate a set of rules to enable cancer registry medical coders to calculate stage using data available to them (registry-derived stage or 'RD-Stage'). Rules for deriving RD-stage (Endometrial carcinoma) were developed using the American Joint Commission on Cancer (AJCC) TNM (tumour, nodes, metastasis) Staging System (8 Edition). An expert working group comprising cancer specialists responsible for delivering cancer care, epidemiologists and medical coders reviewed and endorsed the rules. Baseline completeness of data fields required to calculate RD-Stage, and calculation of the proportion of cases for whom an RD stage could be assigned, was assessed across each Australian jurisdiction. RD-Stage (Endometrial cancer) was calculated by Victorian Cancer Registry (VCR) medical coders and compared with clinical stage recorded by the patient's treating clinician and captured in the National Gynae-Oncology Registry (NGOR). The necessary data completeness level for calculating RD-Stage (Endometrial carcinoma) across various Australian jurisdictions varied from 0 to 89%. Three jurisdictions captured degree of spread of cancer, rendering RD-Stage unable to be calculated. RD-Stage (Endometrial carcinoma) could not be derived for 64/485 (13%) cases and was not captured for 44/485 (9%) cases in NGOR. At stage category level (I, II, III, IV), there was concordance between RD-Stage and NGOR captured stage in 393/410 (96%) of cases (95.8%, Kendall's coefficient = 0.95). A lack of consistency in data captured by, and data sources reporting to, population-based cancer registries meant that it was not possible to provide national endometrial carcinoma stage data at diagnosis. In a sample of Victorian cases, where surgical pathology was available, there was very good concordance between RD-Stage (Endometrial carcinoma) and clinician-recorded stage data available from NGOR. RD-Stage offers promise in capturing endometrial cancer stage at diagnosis for population epidemiological purposes when it is not provided by health services, but requires more extensive validation.